A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms NEXIRI 2-PRODIGE 27; NEXIRI-2
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 23 Jan 2016 Status changed from recruiting to completed as result presented at the 2016 Gastrointestinal Cancers Symposium
- 03 Dec 2012 New trial record